Clinical trial
An Open-label, Single-arm, Phase Ib/IIa Trial to Evaluate the Safety and Efficacy of the EP4 Receptor Antagonist Vorbipiprant (CR6086) in Combination With the PD-1 Inhibitor Balstilimab (AGEN2034), in Patients With Pretreated Mismatch-repair-proficient and Microsatellite Stable Metastatic Colorectal Cancer, and Other Metastatic GI Cancers.
NCT05205330 is registered in ClinicalTrials.gov with Rottapharm Biotech as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Phase Ib/IIa Trial to Evaluate the Safety and Efficacy of the EP4 Receptor Antagonist Vorbipiprant (CR6086) in Combination With the PD-1 Inhibitor Balstilimab (AGEN2034), in Patients With Pretreated Mismatch-repair-proficient and Microsatellite Stable Metastatic Colorectal Cancer, and Other Metastatic GI Cancers.
- Lead sponsor
- Rottapharm Biotech
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- November 23, 2021
- Completion date
- June 30, 2027
- Enrollment
- 107 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
gastric cancer, metastatic gi cancers, metastatic microsatellite-stable colorectal cancer, mismatch repair protein proficient, refractory metastatic colorectal cancer, solid tumor